Stocks / Alpha Vantage News Sentiment

Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest

Protagonist Therapeutics (PTGX) saw its stock climb 7.1% due to investor focus on key pipeline milestones and recent FDA activity related to rusfertide and Icotyde. Despite a P/B ratio of 13.7x, which is high compared to the broader US biotech sector, a discounted cash flow (DCF) model suggests the stock could be trading at a significant 66% discount to its estimated fair value of $412.22. This indicates that the market might be oversizing the execution risks for the company.